Results 11 to 20 of about 20,766 (204)

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry [PDF]

Haematologica, 2014
Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic anemia, bone marrow failure, thrombosis, and, frequently, poor quality of life.
Hubert Schrezenmeier, Petra Muus, Gérard Socié, Jeffrey Szer, Alvaro Urbano-Ispizua, Jaroslaw P. Maciejewski, Robert A. Brodsky, Monica Bessler, Yuzuru Kanakura, Wendell Rosse, Gus Khursigara, Camille Bedrosian, Peter Hillmen   +12 more
doaj   +2 more sources

Paroxysmal nocturnal hemoglobinuria in systemic lupus erythematosus: a case report [PDF]

Journal of Medical Case Reports, 2011
Introduction Paroxysmal nocturnal hemoglobinuria is an acquired disorder of hemopoiesis and is characterized by recurrent episodes of intravascular hemolysis due to an increased sensitivity to complement-mediated hemolysis.
Nakamura Norio, Sugawara Toshiyuki, Shirato Ken-ichi, Kumasaka Ryuichiro, Nakamura Masayuki, Shimada Michiko, Fujita Takeshi, Murakami Reiichi, Shimaya Yuko, Osawa Hiroshi, Yamabe Hideaki, Okumura Ken   +11 more
doaj   +4 more sources

A dog model for acetaminophen-induced fulminant hepatic failure. [PDF]

, 1989
The development of a large animal model of fulminant hepatic failure produced with acetaminophen that should be useful in the development and evaluation of potential medical therapies for the important clinical problem of fulminant hepatic failure is ...
Barone, M, Demetris, J, Francavilla, A, Makowka, L, Polimeno, L, Prelich, J, Starzl, TE, Van Thiel, DH   +7 more
core   +2 more sources

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Danicopan is a first‐in‐class orally administered complement factor D inhibitor, approved as an add‐on therapy to ravulizumab or eculizumab for the treatment of clinically significant extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH).
Chen J, Yang F, Li H, Pradhan R, Ortiz S.   +4 more
europepmc   +2 more sources

Gross Hemoglobinuria and Oliguria are Common Transient Complications of Sclerotherapy for Venous Malformations : Review of 475 Procedures [PDF]

, 2012
Estudi retrospectiu per analitzar la incidència, factors de risc i tractament de la hemoglobinuria macroscòpica i oliguria després del tractament de malformacions venoses amb escleroteràpia.
Barranco Pons, Roger, Perendreu Sans, Joan, Universitat Autònoma de Barcelona. Departament de Medicina, Universitat Autònoma de Barcelona. Facultat de Medicina   +3 more
core   +1 more source

Exertional Hemoglobinuria

The Tohoku Journal of Experimental Medicine, 1975
A 16 years old boy had a typical exertional hemoglobinuria after walking with his new leather shoes on. The attacks of hemoglobinuria were associated with the appearance of an unstable hemoglobin in red cells. A slightly decreased fragility curve by 24 hr incubated red cells, the increase of autohemolysis and the appearance of heat labile hemoglobin ...
YASUHICO OHNO, MASATSUGU SATO, IZUMI KUROKAWA, YOSHIAKI MORIYAMA, OSAMU KOBAYASHI, HIDEAKI SAITO, YASUTAMI KINOSHITA   +6 more
openaire   +3 more sources

Paroxysmal Nocturnal Hemoglobinuria [PDF]

Blood, 2014
AbstractParoxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias. The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH ...
openaire   +2 more sources

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source

Symptom patterns in adult patients stung by scorpions with emphasis on coagulopathy and hemoglubinuria

Journal of Venomous Animals and Toxins including Tropical Diseases, 2012
The aim of this retrospective descriptive study was to highlight clinical manifestations 24-48 hours following referral of adult patients stung by scorpions.
AH Rahmani, A Jalali
doaj   +1 more source

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes [PDF]

, 2017
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis ...
A Hill, A Hill, A Nicholson-Weller, A Roth, AM Risitano, AM Risitano, AM Risitano, AM Risitano, AM Risitano, Antonio M. Risitano, B Nilsson, CE Schoot van der, DJ Araten, DS Holt, E Lach-Trifilieff, E Marchiafava, G Gronowicz, GL Logue, GV Seaman, J Nishimura, J Takeda, JD Tamerius, JE May, JP Atkinson, JV Dacie, L Luzzatto, L Luzzatto, L Luzzatto, M Bessler, M Harboe, M Kono, M Loschi, M Sica, M Sica, MA Lindorfer, Maria De Angioletti, MH Holguin, Michela Sica, MJ Harder, MK Pangburn, MK Pangburn, P Hillmen, P Hillmen, P Hillmen, Patrizia Ricci, PJ Lachmann, PJ Lachmann, RJ Kelly, RL Sparrow, Rosario Notaro, RP Latour de, RP Rother, S Berentsen, SK Krishnan, T Olutogun, T Rondelli, TH Ham, Tommaso Rondelli, UM Reiss, VM Holers, VP Ferreira, WF Rosse, WF Rosse, Z Fishelson, Z Lin   +64 more
core   +2 more sources